Alyeska Investment Group
TRIL

Alyeska Investment Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Alyeska Investment Group’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-22,378
Closed -$292K – 495
2015
Q3 		$292K Buy
22,378
+2,049
+10% +$37.7K ﹤0.01% 441
2015
Q2 		$444K Buy
+20,329
New +$463K 0.01% 456

Other funds holding TRIL

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alyeska Investment Group's TRIL Position: Q4 2015 in Review

Alyeska Investment Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2015, closing a stake of 22,378 shares — an estimated $292K sold.

Alyeska Investment Group first reported a position in TRIL in Q2 2015 and held it in 2 quarters. The position peaked at $444K in Q2 2015. 29 funds tracked by Wall St. Rank hold TRIL as of Q4 2015.

  • Alyeska Investment Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 22,378 Trillium Therapeutics Inc. shares in Q4 2015, an estimated $292K.
  • Alyeska Investment Group first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 2 quarters.
  • Alyeska Investment Group's Trillium Therapeutics Inc. position peaked at $444K in Q2 2015.
  • 29 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2015.

Based on Alyeska Investment Group's 13F filing for Q4 2015, filed 16 Feb 2016.